Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments

Journal of Hypertension

Volumn 16, Issue 2, 1998, Pages 127-137

  Black, H ^a   Boissel, J P ^a   Brenner, B ^a   Brown, M ^a   Bulpitt, C ^a   Chalmers, J ^a   Collins, R ^a,a   Cutler, J ^a   Dahlof, B ^a   Davis, B ^a   Fagard, R ^a   Fletcher, A ^a   Furberg, C ^a   Hansson, L ^a,a   Kuramoto, K ^a   Lewis, E ^a   MacMahon, S ^a   Mancia, G ^a   Pitt, B ^a   Poulter, N ^a   Remuzzi, G ^a   Sleight, P ^a   Turner, R ^a   Sever, P ^a   Whelton, P ^a   Wing, L ^a   Yusuf, S ^a   Zanchetti, A ^a   Martin, I ^a   Cohn, J ^a   Alderman, M ^a   Neal, B ^a   Rodgers, A ^a   Baigent, C ^a   more..

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium antagonists; Coronary heart disease; Meta analysis; Overview; Randomized trials; Stroke

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE; NITRENDIPINE; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; GENDER; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTER; STROKE;

EID: 0007245215     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part I, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
2. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
3. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C, on behalf of the UKTIA Collaborative Group. Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ 1996; 313:147.
4. Flack JM, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92:2437-2445.
5. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. N Engl J Med 1972; 287:781-787.
6. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
7. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839.
8. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4:265-271.
9. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
10. Kostis JB, Davis BR, Cutler J, Grimm R, Berge K, Cohen J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension (ISH). JAMA 1997; 278:212-216
11. Yusuf S. Thomas T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989; 13:74-79.
12. Medical Research Council Working Party. MRC Trial of treatment of mild hypertension. Principal results. BMJ 1985; 291:97-104
13. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
14. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
15. Wilhelmsen L, Berglund G, Elmfeld D. Beta-blockers versus diuretics in hypertensive men. Main results from the HAPPHY trial. J Hypertens 1987; 5:561-576.
16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371.
17. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomised controlled trials. Eur Heart J 1997; 18:560-565.
18. Neaton JD, Grimm RHJ, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270:713-724.
19. Materson B. Department of Veteran Affairs single drug therapy of hypertension: final results. Am J Hypertens 1993; 8:189-192.
20. The GLANT Study Group. A 12-month comparison of ACE-inhibitor and Ca-antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Hypertens Res 1995, 18:235-244.
21. Borhani N, Mercuri M, Borhani P, Buckalew V, Canossa-Terris M, Carr A, et al. Final outcome results of the Multicentre Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785-791.
22. Staessen J, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhager W, et al. for the SYST-EUR Study Group. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
23. Gong L, Zhang W, Zhu Y, Zhu J, 11 collaborating centres in the Shanghai area, Kong D, Page V. et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14:1237-1245.
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456.
25. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2067.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
27. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina [overview]. BMJ 1989; 229:1187-1192.
28. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67:1295-1297.
29. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB. Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997; 96:856-863.
30. Packer M, O'Connor C, Ghali J, Pressler M, Carson P, Belkin R, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.
31. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15:105-115.
32. Sharpe N. The effects of ACE inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol 1993; 22 (suppl 10):S9-S12.
33. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Clin Exp Hypertens 1996; 18:489-499.
34. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statist Med 1987; 6:245-250.
35. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Volume 1: worldwide evidence 1985-1990. Oxford: Oxford University Press. 1990.
36. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339:1-15, 71-85.
37. Chalmers I, Haynes B. Reporting, updating, and correcting systematic reviews of the effects of health care. BMJ 1994; 309:862-865.
38. Schrier RW, Savage S. Appropriate blood pressure control in type II diabetes (ABCD trial): implications for complications Am J Kidney Dis 1992; 20:653-657.
39. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996; 9:342-360.
40. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Australian comparative outcome trial of angiotensin converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997; 24:188-192.
41. The CAPPP Group. The captopril prevention project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 1990; 8:985-990.
42. Zanchetti A, on behalf of the ELSA Investigators. Prevalence of carotid atherosclerosis in hypertension: preliminary data from the European Lacidipine Study on Atherosclerosis. Blood Pressure 1996; 5 (suppl 4):30-35.
43. Hypertension in Diabetes Study Group. Hypertension in diabetes study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39:1554-1561.
44. The HOPE Study Investigators. The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12:127-137.
45. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Blood Pressure 1995; 3:313-319.
46. Bulpitt C, Fletcher A, Amery A, Coope J, Grimley Evans J, Lightowers S, et al. The hypertension in the very elderly trial (HYVET). Drugs Ageing 1994; 5:171-183.
47. Brown M, Castaigne A, Ruilope LM, Mancia G, Rosenthal T. de Leeuw PW, et al. INSIGHT - international nifedipine GITS study intervention as a goal in hypertension treatment. J Hum Hypertens 1996; 10 (suppl 3):157S-160S.
48. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T. Ibsen H, et al. for the LIFE Study Group. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, design, and methods. J Hypertens 1997; 10:705-713.
49. Kuramoto K, and the National Intervention Co-operative Study Group. Treatment of elderly hypertensives in Japan: national intervention co-operative study in elderly hypertensives. J Hypertens 1994; 12 (suppl 6):S35-S40.
50. The NORDIL Group. The Nordic diltiazem study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure 1993; 2:312-321.
51. The PHYLLIS Project Group. Plaque hypertension lipid-lowering Italian study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive patients. J Hypertens 1993; 11 (suppl 5):S314-S315.
52. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996; 14 (suppl 2):S41-S46.
53. Lees R, Pitt B, Chan R, Holmvang G, Dinsmore R, Campbell L, et al. Baseline clinical and angiographic data in the Quinapril lschaemic Event Trial (QUIET). Am J Cardiol 1996; 78:1011-1016.
54. Malacco E, Gnemmi A, Romagnoli A, Coppini A, on behalf of the SHELL Study Group. Systolic hypertension in the elderly: long-term lacidipine treatment. J Cardiovasc Pharmacol 1994; 23 (suppl 5):S62-S66.
55. Dahlof B, Hansson L, Lindholm L, Schersten B, Wester P, Ekbom T, et al. STOP-Hypertension-2: A prospective intervention trial of 'newer' versus 'older' treatment alternatives in old patients with hypertension. Blood Pressure 1993; 2:136-141.
56. Zanchetti A, Magnani B, Dal Palu C, on behalf of the Verapamil Hypertension Atherosclerosis Study V. Atherosclerosis and calcium antagonists: the VHAS. J Hum Hypertens 1992; 6 (suppl 2): S45-S48.